Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.75USD
4:00pm EDT
Change (% chg)

$0.03 (+4.81%)
Prev Close
$0.71
Open
$0.70
Day's High
$0.76
Day's Low
$0.67
Volume
1,183,686
Avg. Vol
404,096
52-wk High
$3.41
52-wk Low
$0.65

Chart for

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.56
Market Cap(Mil.): $96.95
Shares Outstanding(Mil.): 141.07
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.88 -- --
ROI: -35.26 -0.73 12.97
ROE: -44.69 -2.77 14.84

BRIEF-Celldex Therapeutics Approves Workforce Reduction

* CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS

Apr 24 2018

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

Apr 16 2018

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

Mar 07 2018

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

Nov 17 2017

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Nov 07 2017

Earnings vs. Estimates